Impact of Serum GDF-15 and IL-6 on Immunotherapy Response in Cancer
Author Information
Author(s): Akdogan Orhun, Turkmen Sena, Uyar Galip Can, Yucel Kadriye Bir, Tufekci Busra, Gurler Fatih, Yazici Ozan, Ozdemir Nuriye, Ozet Ahmet, Karakaya Cengiz, Sutcuoglu Osman, Moreno Carlos S.
Primary Institution: Gazi University
Hypothesis
This study aims to evaluate the relationship between serum GDF-15 and IL-6 levels and their impact on immunotherapy response in cancer patients.
Conclusion
Elevated serum GDF-15 levels were identified as a significant predictor of shorter progression-free survival and overall survival, as well as an increased risk of cachexia in patients receiving immunotherapy for advanced cancers.
Supporting Evidence
- High levels of GDF-15 were associated with worse survival outcomes.
- Patients with elevated GDF-15 levels had a higher likelihood of cancer-related cachexia.
- IL-6 also showed potential as a biomarker, but its impact was less pronounced than GDF-15.
- Patients in the low-GDF-15 group had significantly longer median progression-free survival.
- Cachexia was observed in 43% of patients with high GDF-15 levels.
Takeaway
Doctors are trying to find out if certain blood markers can help predict how well cancer patients will respond to immunotherapy. They found that high levels of one marker, GDF-15, might mean the treatment won't work as well.
Methodology
This was a prospective observational study involving 85 patients with advanced cancers treated with nivolumab, measuring serum levels of GDF-15 and IL-6 using ELISA kits.
Potential Biases
Potential biases may arise from the exclusion of patients with certain comorbid conditions and the requirement for prior treatment before receiving nivolumab.
Limitations
The sample size may affect the generalizability of the findings, and biomarker levels were only assessed at baseline.
Participant Demographics
The cohort included 58 males (68%) and 27 females (32%), with a median age of 64.5 years.
Statistical Information
P-Value
0.020
Confidence Interval
95% CI: 0.25–0.90
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website